Kengreal FDA Approval History
FDA Approved: Yes (First approved June 22, 2015)
Brand name: Kengreal
Generic name: cangrelor
Dosage form: for Injection
Company: The Medicines Company
Treatment for: Percutaneous Coronary Intervention
Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.
Development Timeline for Kengreal
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.